ME News reports that on August 20 (UTC+8), Moderna and Merck’s AI-assisted personalized mRNA cancer therapy achieved success in a large Phase 3 clinical trial involving 1,137 patients. The therapy uses AI to compare tumor and healthy DNA sequences, precisely identifying the most immunogenic mutations and customizing a personalized vaccine encoding up to 34 neoantigens. Previous five-year follow-up data showed that when combined with Keytruda, the therapy increased cancer-free survival rates to 68.8% in high-risk melanoma patients, reducing the risk of recurrence or death by 49% and the risk of distant metastasis by 59%. This Phase 3 trial breakthrough marks a new era in personalized tumor immunotherapy.（Source: X platform）
Moderna and Merck’s AI-driven mRNA cancer therapy succeeds in Phase 3 trial
KuCoinFlashShare
Summary
Moderna and Merck’s AI-driven mRNA cancer therapy successfully passed a pivotal Phase 3 trial involving 1,137 patients. The treatment uses artificial intelligence to identify immunogenic mutations and produces personalized vaccines containing up to 34 neoantigens. Five-year data revealed a 68.8% cancer-free survival rate when combined with Keytruda, reducing the risk of recurrence or death by 49% and distant metastasis by 59%. The results provide compelling evidence for the future of personalized cancer care, with a favorable risk-to-reward profile for long-term patient outcomes.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.